Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Autoimmune Disorders

Free Subscription 05.01.2026 2 Ann Neurol 2 BMC Neurol 2 Intern Med 2 J Autoimmun 3 J Immunol 3 J Neuroimmunol 4 J Neurol 2 J Rheumatol 1 Kidney Int 13 Mult Scler 3 Neurology 4 PLoS One 2 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. SABATINO JJ JR, Cree BAC, Hauser SL
   Reply to "New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond".
   Ann Neurol. 2025 Dec 24. doi: 10.1002/ana.78124.
   PubMed        
   
   
2. BIRNBAUM G
   New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
   Ann Neurol. 2025 Dec 24. doi: 10.1002/ana.78121.
   PubMed        
   
   

   
   BMC Neurol

3. ALNAJASHI H, Almohammed HAJ, Morad AS, Bin Saddiq BW, et al
   Safety and efficacy of oral cladribine in relapsing multiple sclerosis: a systematic review and meta-analysis.
   BMC Neurol. 2025;25:510.
   PubMed         Abstract available
   
   
4. FLORESCU AM, Bryrup T, Nilsson AC, Blaabjerg M, et al
   Anti-NMDAR antibodies are not prevalent in Lyme neuroborreliosis: a retrospective cohort study.
   BMC Neurol. 2025;25:518.
   PubMed         Abstract available
   
   

   
   Intern Med

5. AKAHANE T, Yamaguchi Y, Kobayashi R, Kawai S, et al
   Longitudinal Changes in Structural and Functional Brain Imaging and their Association with Cognitive and Neuropsychiatric Symptoms in Hashimoto Encephalopathy with Anti-NAE Antibody.
   Intern Med. 2025 Dec 25. doi: 10.2169/internalmedicine.6395.
   PubMed         Abstract available
   
   
6. KAWANISHI M, Douhara A, Ishida K, Nakatsuji M, et al
   Tumor-associated Pancreatitis Mimicking Autoimmune Pancreatitis in a Young Male: A Case of Main Duct IPMC.
   Intern Med. 2025 Dec 25. doi: 10.2169/internalmedicine.6037.
   PubMed         Abstract available
   
   

   
   J Autoimmun

7. ROCCATELLO D, Barinotti A, Radin M, Cecchi I, et al
   Daratumumab monotherapy reverses the immune and pro-fibrotic profiles in refractory lupus nephritis patients: a pilot case study.
   J Autoimmun. 2025;158:103520.
   PubMed         Abstract available
   
   
8. TALAMINI L, Verdot C, Shoenfeld Y, Muller S, et al
   Pathophysiological effects of long COVID-19 (auto)antibodies on fertility.
   J Autoimmun. 2025;158:103518.
   PubMed         Abstract available
   
   

   
   J Immunol

9. OLEINIKA K, Correia Ferreira A, Mouftakir S, Castrillon C, et al
   Dynamic control of autoreactive B cells from spontaneous germinal centers.
   J Immunol. 2025;214:3208-3217.
   PubMed         Abstract available
   
   
10. ROY U, Raghavan SC
    Regulation of B-cell development and differentiation by microRNAs during immune response and their implications in immunological disorders.
    J Immunol. 2025;214:3199-3207.
    PubMed         Abstract available
    
    
11. PANDEY JP
    Immunoglobulin GM (gamma marker) allotypes and their role in immune response and disease susceptibility.
    J Immunol. 2025;214:3181-3187.
    PubMed         Abstract available
    
    

    
    J Neuroimmunol

12. BUNGANIC R, Revendova KZ, Hradilek P, Kusnierova P, et al
    Comparison of SIMOA and VEUS technologies for serum glial fibrillary acidic protein measurement.
    J Neuroimmunol. 2026;411:578825.
    PubMed         Abstract available
    
    
13. BOLDRINI V, Carnero Contentti E
    Limited availability of live CBA for AQP4-IgG testing and its consequences for the diagnosis and treatment of NMOSD in Latin American countries.
    J Neuroimmunol. 2026;411:578817.
    PubMed         Abstract available
    
    
14. PIEDRABUENA MA, Marrodan M, Zarate MA, Fiol M, et al
    Characterizing double seronegative neuromyelitis optica spectrum disorder: A distinct subgroup or part of the continuum?
    J Neuroimmunol. 2026;411:578822.
    PubMed         Abstract available
    
    

    
    J Neurol

15. CHISARI CG, Lo Fermo S, Di Sapio A, Amato MP, et al
    Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).
    J Neurol. 2025;273:47.
    PubMed         Abstract available
    
    
16. RESTUCCIA G, Susinna C, Marafioti G, Rifici C, et al
    Serum and cerebrospinal fluid biomarkers as predictors of cognitive impairment in multiple sclerosis: a systematic review of longitudinal studies.
    J Neurol. 2025;273:36.
    PubMed         Abstract available
    
    
17. SURCINELLI A, Massa I, Gentili N, Panzera I, et al
    Harmonized magnetic resonance imaging protocols for multiple sclerosis: HARMONY-MS, a pilot project.
    J Neurol. 2025;273:39.
    PubMed         Abstract available
    
    
18. YANG J, Li H, Zhang Y, Hu S, et al
    Correction: Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
    J Neurol. 2025;273:51.
    PubMed        
    
    

    
    J Rheumatol

19. TAUBMANN J, Hagen M, Muller F, Wirsching A, et al
    Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis.
    J Rheumatol. 2026;53:33-37.
    PubMed         Abstract available
    
    
20. WEISS PF, Ruperto N, Quebe-Fehling E, Shew A, et al
    Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.
    J Rheumatol. 2026;53:85-94.
    PubMed         Abstract available
    
    

    
    Kidney Int

21. BARBOUR SJ, Hladunewich MA, McCaleb ML, Robson R, et al
    A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy.
    Kidney Int. 2025 Dec 22:S0085-2538(25)01007-5. doi: 10.1016/j.kint.2025.
    PubMed         Abstract available
    
    

    
    Mult Scler

22. MARRIE RA, Dobson R, Baranzini SE, Salvetti M, et al
    Toward a global research agenda for preventing multiple sclerosis.
    Mult Scler. 2025 Dec 26:13524585251398381. doi: 10.1177/13524585251398381.
    PubMed         Abstract available
    
    
23. BRIGGS F, Nyati A, Zweig S, Leung LJ, et al
    Allergic phenotypes and asthma in multiple sclerosis: Epidemiologic and genetic relationships.
    Mult Scler. 2025 Dec 27:13524585251398382. doi: 10.1177/13524585251398382.
    PubMed         Abstract available
    
    
24. KIM SH, Kang YR, Chung J, Joo M, et al
    Optimizing kappa free light chain index thresholds for multiple sclerosis (MS) diagnosis in low-MS prevalence regions: Insights from an Asian cohort.
    Mult Scler. 2025 Dec 27:13524585251399102. doi: 10.1177/13524585251399102.
    PubMed         Abstract available
    
    
25. ITO M, Masuda H, Morooka M, Sugiyama A, et al
    Gerstmann-Straussler-Scheinker disease mimicking primary progressive multiple sclerosis: A case with positive oligoclonal bands.
    Mult Scler. 2025 Dec 29:13524585251401053. doi: 10.1177/13524585251401053.
    PubMed         Abstract available
    
    
26. DE NAPOLI G, Gotti E, Baldovini C, Di Sciascio L, et al
    Cardiogenic shock after ocrelizumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2025 Dec 31:13524585251407501. doi: 10.1177/13524585251407501.
    PubMed         Abstract available
    
    
27. RATZAN AS, Simani L, Dworkin JD, Buyukturkoglu K, et al
    Characterizing the extended language network in individuals with multiple sclerosis.
    Mult Scler. 2025 Dec 31:13524585251398451. doi: 10.1177/13524585251398451.
    PubMed         Abstract available
    
    
28. GUHA NIYOGI P, Sanjayan M, Ghosal R, Goldsmith J, et al
    Quantifying observable movement reserve in multiple sclerosis via upper diurnal activity quantiles.
    Mult Scler. 2026 Jan 1:13524585251398689. doi: 10.1177/13524585251398689.
    PubMed         Abstract available
    
    
29. RANUCCI D, Falco F, Nicolella V, Marra LA, et al
    Dysarthria assessment in multiple sclerosis patients.
    Mult Scler. 2026;32:134-143.
    PubMed         Abstract available
    
    
30. MOROZUMI T, Preziosa P, Meani A, Pagani E, et al
    Contribution of structural and functional MRI in predicting response to motor training in multiple sclerosis.
    Mult Scler. 2026;32:93-106.
    PubMed         Abstract available
    
    
31. LIZAK N, Sharmin S, Horakova D, Havrdova EK, et al
    Managing reactivation of multiple sclerosis during treatment with natalizumab.
    Mult Scler. 2026;32:121-133.
    PubMed         Abstract available
    
    
32. BORRELLI S, Guisset F, Farneti M, Stolting A, et al
    Dietary habits and advanced imaging/laboratory markers in multiple sclerosis: An exploratory cross-sectional study.
    Mult Scler. 2026;32:69-79.
    PubMed         Abstract available
    
    
33. CALABRESI PA, Giovannoni G, Hartung HP, Naismith RT, et al
    Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial.
    Mult Scler. 2026;32:107-120.
    PubMed         Abstract available
    
    
34. BERNSTEIN HR, Grouza V, Gati JS, Morrow SA, et al
    Periventricular gradients in axonal and myelin microstructure are present in people with multiple sclerosis having low and high disability.
    Mult Scler. 2026;32:80-92.
    PubMed         Abstract available
    
    

    
    Neurology

35. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214473.
    PubMed         Abstract available
    
    
36. BARTELS F, Tapuc A, Rentzsch K, Duong SL, et al
    Memory Deficits in Cancer Patients With Serum NMDA Receptor Autoantibodies.
    Neurology. 2026;106:e214490.
    PubMed         Abstract available
    
    
37. MOCCIA M, Silbermann E
    Can Once-Yearly Rituximab Dosing Be "Enough" for Most People With Relapsing Multiple Sclerosis?
    Neurology. 2026;106:e214586.
    PubMed        
    
    

    
    PLoS One

38. PRUST ML, Lalama CM, Kehlenbrink S, Akinola OA, et al
    Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh.
    PLoS One. 2026;21:e0333652.
    PubMed         Abstract available
    
    
39. CARDINI R, Gervasoni E, Germanotta M, Aprile IG, et al
    Consensus on recommended evaluation tools in multiple sclerosis (CORE-MS): A Delphi study protocol on balance and gait assessment.
    PLoS One. 2026;21:e0337440.
    PubMed         Abstract available
    
    
40. HE Z, Li W, Huang X, Ma S, et al
    Apathy in patients with Neuromyelitis Optica Spectrum Disorder.
    PLoS One. 2025;20:e0339479.
    PubMed         Abstract available
    
    
41. BUCHKA S, Havla J, On BI, Rehms R, et al
    Individual-level surrogacy of MRI lesions for disease severity in RRMS: Methods to quantify predictive power and their application to longitudinal data from recent trials.
    PLoS One. 2025;20:e0337893.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

42. GUAN Y, Yu Y, Fu M, Xu H, et al
    Enhanced insulin signaling via circulating ATG7: A potential therapeutic strategy for diabetes.
    Proc Natl Acad Sci U S A. 2026;123:e2503783123.
    PubMed         Abstract available
    
    
43. FRATUS M, Alam MA
    A closed-loop microneedle-integrated physiological model for predictive glycemic management.
    Proc Natl Acad Sci U S A. 2025;122:e2523517122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.